Home › NCT05708755

CMV Immunity Monitoring in Lung Transplant Recipients

Cytomegalovirus T Cell Immunity and Antiviral Prophylaxis Minimization in Lung Transplant Recipients

Who can join

Ages 18 to 99 · All sexes

Inclusion Criteria:

1. Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health
2. Pre-existing serological immunity to CMV (R+)
3. Able and willing to provide informed consent

Exclusion Criteria:

1. Anti-thymocyte globulin induction immunosuppression
2. Perioperative desensitization
3. Pregnant or breastfeeding women

About the study

The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.

What is being tested

• Cytomegalovirus T Cell Immunity Panel (CMV-TCIP) (device)
• Donor-Derived Cell-Free DNA (dd-cfDNA) Assay (diagnostic test)
• Valganciclovir (drug)

Sponsor: NYU Langone Health · Participants: 50 · Started: Sep 13, 2024

Contact the study team

• Tyler Lewis · Phone: 866-838-5864

Official record on ClinicalTrials.gov — NCT05708755

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.